trending Market Intelligence /marketintelligence/en/news-insights/trending/WQWMkHksguniCDNiUI21-w2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Camurus, Braeburn's opioid addiction therapy gets tentative FDA approval

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Camurus, Braeburn's opioid addiction therapy gets tentative FDA approval

Camurus AB (publ) and its U.S. partner Braeburn Inc.'s opioid use disorder treatment Brixadi was granted tentative approval by the U.S. Food and Drug Administration.

Brixadi is an extended-release injection given under the skin that is used to treat patients who are receiving buprenorphine, the current standard of care for opioid withdrawal.

Sweden-based Camurus said the final approval of a monthly dosage of the drug will be granted by the FDA once the exclusivity period granted to Indivior PLC's Sublocade, also an extended-release buprenorphine, comes to an end.

Camurus said the restriction period may not last longer than November 2020 and could be reduced if successfully challenged. India's Dr. Reddy's Laboratories Ltd. has been in a legal tussle with Indivior to launch a generic version of Suboxone.

Brixadi, which will be available in weekly and monthly formulations, works by releasing buprenorphine at a steady rate, blocking the so-called drug-liking effect of opioids in the brain and reducing withdrawal and drug-craving symptoms, thus reducing the likelihood that patients will take illicit opioids.

The U.S. FDA's decision was based on positive data from seven clinical trials showing the efficacy and safety of Brixadi. It follows the European approval of the same drug, known as Buvidal outside the U.S., to treat opioid dependence in people aged 16 years and older.

Treatments for opioid use disorder, which affects more than 2 million Americans and caused at least 72,000 overdose deaths in 2017, has received urgent attention from the FDA. In December, Novartis AG's and Pear Therapeutics Inc.'s reSET-O became the first prescription digital therapeutic approved by the U.S. regulator to treat opioid use disorder, while in November, eight medical device companies, ranging from therapeutics to diagnostic capabilities, were selected by the FDA for their submitted development plans to help combat the opioid crisis.

However, there has been a debate on the efficacy of extended-release opioid treatments. In October, the U.S. pricing watchdog the Institute for Clinical and Economic Review found that the cost of treatments for opioid use disorder far exceeds its thresholds for cost-effectiveness. ICER also found insufficient evidence that extended-release medications provide a greater net health benefit than buprenorphine and naloxone.